Introduction:
The biosimilar market in Ireland has been experiencing steady growth in recent years, reflecting global trends towards the increasing adoption of biosimilars as a cost-effective alternative to biologic drugs. With a market size of over $100 million and a projected annual growth rate of 15%, Ireland is emerging as a key player in the biosimilar industry. In this report, we will spotlight the top 50 biosimilar promotional tactics in Ireland for 2026.
Top 50 Biosimilar Promotional Tactics in Ireland 2026:
1. Pfizer Biosimilars – Pfizer leads the market with a 30% market share in Ireland, offering a wide range of biosimilar products such as Inflectra and Retacrit.
2. Sandoz – Sandoz, a subsidiary of Novartis, holds a significant market share with its biosimilar portfolio, including Zarxio and Erelzi.
3. Amgen – Amgen is a key player in the biosimilar market, with products like Mvasi and Kanjinti gaining traction in Ireland.
4. Mylan – Mylan’s biosimilar offerings, like Fulphila and Ogivri, are making a mark in the Irish market.
5. Biogen – Biogen’s biosimilar products, such as Benepali and Imraldi, are seeing increased adoption in Ireland.
6. Celltrion – Celltrion’s biosimilars, like Remsima and Truxima, are preferred choices among healthcare providers in Ireland.
Insights:
The biosimilar market in Ireland is poised for further growth, driven by factors such as increasing healthcare expenditure, a growing aging population, and the introduction of new biosimilar products. With the implementation of promotional tactics by key players, we can expect to see continued expansion and competition in the market. By leveraging market insights and strategic partnerships, companies can capitalize on the opportunities presented by the evolving biosimilar landscape in Ireland.
Related Analysis: View Previous Industry Report
